Shenzhen YHLO Biotech (688575) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 397.82 million, down 4.78% year-over-year; net profit attributable to shareholders rose 76.89% to RMB 17.95 million.

• Adjusted net profit (excluding non-recurring items) fell 33.01% year-over-year to RMB 24.72 million.

• Cash flow from operations surged to RMB 90.27 million, up 1,400.96% year-over-year.

• Domestic and overseas business saw mixed performance, with overseas revenue up 17.21% and domestic slightly down.

Financial highlights

• Gross margin improved as cost of sales dropped to RMB 150.01 million from RMB 169.26 million year-over-year.

• R&D investment totaled RMB 66.18 million, representing 16.64% of revenue.

• Total assets at quarter-end were RMB 4.30 billion, up 0.28% from year-end 2025.

• Basic and diluted EPS both increased to RMB 0.03, up 50% year-over-year.

Outlook and guidance

• Company continues to expand its installed base of chemiluminescence analyzers, with cumulative installations exceeding 13,680 units.

• Coverage in top-tier hospitals remains strong, with products used in over 70% of top hospitals nationwide.